FemHealth Ventures Closes Oversubscribed $65 Million Fund II

女性健康风险投资公司完成超额认购的6500万美元基金II

SHORT HILLS, N.J., December 17, 2025-- FemHealth Ventures, a leading women’s health-focused venture capital firm, a top-decile performer across DPI and IRR for Fund I, announced the close of FemHealth Ventures Fund II at $65 million. The oversubscribed raise brings the firm’s assets under management to $100 million across two funds and further solidifies FemHealth Ventures’ position as a category-defining investor in women’s health innovation..

新泽西州肖特山，2025年12月17日——FemHealth Ventures是一家专注于女性健康的风险投资公司，其第一支基金在DPI和IRR方面表现位列前十分之一。公司宣布成功募集6500万美元，完成FemHealth Ventures第二支基金的募集。此次超额认购使得公司管理资产规模达到1亿美元，横跨两支基金，进一步巩固了FemHealth Ventures作为女性健康创新领域标杆投资者的地位。

The fund received significant support from existing limited partners alongside new investors aligned with the firm’s mission to transform women’s health while achieving exceptional financial returns. FemHealth Ventures Fund I, launched in 2021, is recognized as a top-decile performer across DPI and IRR according to Carta and Pitchbook databases..

该基金获得了现有有限合伙人的重要支持，同时也吸引了与公司使命一致的新投资者，即在实现卓越财务回报的同时，推动女性健康领域的变革。根据Carta和Pitchbook数据库显示，2021年推出的FemHealth Ventures Fund I在DPI和IRR方面被公认为表现排名前十的基金。

“We are thrilled to announce the successful close of Fund II, more than doubling the size of our inaugural fund,” said Maneesha Ghiya, Managing Partner of FemHealth Ventures. “This raise reflects growing recognition that women’s health innovation offers both substantial societal impact and compelling investment potential.

“我们很高兴地宣布，第二基金成功结束，规模比我们的首个基金增加了一倍多，”FemHealth Ventures的管理合伙人马尼莎·吉亚表示。“此次募资反映了人们日益认识到，女性健康创新不仅具有重大的社会影响，还具备吸引人的投资潜力。”

We are grateful for the trust our limited partners continue to place in us.”.

我们感谢有限合伙人对我们的持续信任。

FemHealth Ventures is widely recognized for establishing the industry’s three-category framework defining women’s health as conditions that appear only in women, mostly in women, or differently in women. First introduced in 2019 as part of the FemHealth Framework (© 2019 FemHealth Ventures), this model is now widely used across the sector to guide research, strategy, and investment..

FemHealth Ventures 因建立行业三类框架而广受认可，该框架将女性健康定义为仅在女性中出现、主要在女性中出现或在女性中表现不同的状况。这一模型最早于2019年作为 FemHealth 框架（© 2019 FemHealth Ventures）的一部分提出，如今已被业界广泛用于指导研究、战略和投资。

“The next generation of transformative women’s health companies will be led by visionary founders, and we are honored to support them,” added Sara Crown Star, Venture Partner at FemHealth Ventures.

“下一代变革性的女性健康公司将由富有远见的创始人领导，我们很荣幸能够支持他们，” FemHealth Ventures 的风险合伙人莎拉·克朗·斯塔尔补充道。

Fund II will continue investing across drugs, devices, diagnostics, and digital / AI-enabled technologies that address unmet needs in women’s health. Fund II remains focused on partnering with exceptional founders who are building solutions that materially improve lives.

基金 II 将继续投资于药物、设备、诊断以及数字化/人工智能技术，以满足女性健康领域未被满足的需求。基金 II 仍专注于与杰出的创始人合作，共同打造能够显著改善生活的解决方案。

About FemHealth Ventures

关于FemHealth Ventures

FemHealth Ventures is a women’s health–focused venture capital firm investing in breakthrough innovations that deliver meaningful health advances and strong investor returns. The firm has been featured in Forbes, The Wall Street Journal, Insider, and CNBC and manages $100 million in assets.

FemHealth Ventures 是一家专注于女性健康的风投公司，投资于能够带来显著健康进步和强劲投资回报的突破性创新。该公司曾被《福布斯》、《华尔街日报》、Insider 和 CNBC 报道，管理着 1 亿美元的资产。

For more information, visit www.femhealthventures.com.

欲了解更多信息，请访问 www.femhealthventures.com。

Contact:

联系：

Media Contact

媒体联系人

Email: info@femhealthventures.com

电子邮件：info@femhealthventures.com